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Insulin resistance refers to the inability of insulin to
regulate systemic glucose metabolism. This condition
is known to play a major role in the deleterious meta-
bolic features associated with excess body weight.1 As
an underlying pathophysiological factor linked to the
metabolic syndrome,2 insulin resistance increases
the risk of all causes of cancer and cardiovascular dis-
ease mortality.3,4 Among the mediators of insulin
resistance associated with obesity, visceral adipose
tissue (VAT) appears to play a relevant role in the
development and maintenance of this disturbance. The
amount of VAT has been shown to be the best
predictor of insulin resistance measured by the clamptechnique,5-7 and it showed the strongest correlation
with HOMA-IR according to a recent meta-analysis.8
This is because the dysfunctional visceral adipose tissue
associated with obesity secretes several factors that
play relevant roles in obesity and obesity-related
comorbidities.9 However, the specific mechanism by
which VAT becomes dysfunctional in promoting
obesity-related complications, such as insulin resis-
tance, must be fully disclosed.
Insulin resistance is known to be modulated by both
genetic and environmental influences.10 The interaction
between these factors in the disease development can be
mediated by epigenetic modifications. Epigenetic
markers might explain the link between lifestyle and
the risk of disease and have been proposed to be sensi-
tive biomarkers and potential therapeutic targets for dis-
ease management.11 Among epigenetic mechanisms,
DNA methylation is the best studied epigenetic regula-
tory mechanism. DNA methylation has been proposed
as a next-generation biomarker with great diagnostic
and prognostic promise for clinicians.12 In this context,
previous studies have explored epigenetic involvement
in obesity.13 Moreover, the methylome of human
pancreatic islets associated with type 2 diabetes (T2D)
has been characterized, demonstrating that altered
DNA methylation in human islets contributes to per-
turbed hormone secretion and the pathogenesis of
T2D.14 Furthermore, DNA methylation levels in adi-
pose tissue have been related to alterations in glucose
metabolism.15 Differences in the methylation levels of
VAT have also been identified by comparing patients
with and without metabolic syndrome through a
genome-wide differential methylation analysis.16 How-
ever, the methylome of VAT has not been explored until
now in insulin-resistant (IR) patients classified by the
clamp technique, the gold-standard method for evalu-
ating insulin sensitivity.17
The present study aimed to disentangle the epigenetic
basis of insulin resistance by performing a genome-
wide epigenetic analysis in VAT from morbidly obese
patients depending on the insulin sensitivity evaluated
by the clamp technique.SUBJECTS AND METHODS
Study participants. A group of morbidly obese Cauca-
sian patients (n 5 36) with different degrees of insulin
Translational Research
Volume-, Number- Crujeiras et al 3sensitivity were included in this study. We first evalu-
ated a discovery cohort (n 5 5 insulin-sensitive (IS)
and n 5 7 IR morbidly obese participants). An
extended validation cohort composed of 24 morbidly
obese Caucasian patients with different degrees of
insulin sensitivity was analyzed (n 5 13 IS and
n 5 11 IR). All participants were recruited at the
Endocrinology Service of the University Hospital of
Dr. Josep Trueta (Girona, Spain). All subjects
confirmed that their body weight had been stable for
$3 months before the study. Written informed
consent to participate in the trial was obtained before
the beginning of the study, in agreement with the
Declaration of Helsinki, and the study was performed
following the national and European Union
guidelines. The protocol of this study was approved
by the Hospital Ethics Committee.
VAT samples were obtained during elective surgical
procedures (cholecystectomy, surgery for abdominal
hernia and gastric bypass surgery), washed, and immedi-
ately flash-frozen in liquid nitrogen before being stored
at280C.Anthropometric, biochemical determinations,
and an euglycemic-hyperinsulinemic clamp for insulin
action measurement were implemented as aforemen-Table I. Anthropometric and clinical parameters of study
IS
Discovery cohort
N 5
Gender (men/women) 1/4
Age (y) 53.2 6 10.3
BMI (kg/m2) 39.4 6 7.8
Waist (cm) 111.4 6 13.7
Fasting glucose (mg/dl) 93 6 14.9
HbA1c (%) 5.2 6 0.4
Euglycemic clamp (mg/kg$min) 7.4 6 1.6
Total-cholesterol (mg/dl) 202.6 6 27.2
LDL-cholesterol (mg/dl) 128 6 25.3
HDL-Cholesterol (mg/dl) 57 6 8.8
Triglycerides (mg/dl) 68 (57–128)
C-reactive protein (mg/dl) 0.54 (0.28–0.76)
Validation cohort
N 13
Gender (men/women) 1/12
Age (y) 45.3 6 11.4
BMI (kg/m2) 45.2 6 6.9
Waist (cm) 120.3 6 12.2
Fasting glucose (mg/dl) 96.4 6 24.1
HbA1c (%) 5.57 6 0.46
Euglycemic clamp (mg/kg$min) 6.44 6 1.4
Total-cholesterol (mg/dl) 179.4 6 36.5
LDL-cholesterol (mg/dl) 114.5 6 29.8
HDL-cholesterol (mg/dl) 47.2 6 6.3
Triglycerides (mg/dl) 82 (72–95)
C-reactive protein (mg/dl) 0.8 (0.45–1.31)
Bold values indicate statistically significant data (P , 0.05).
Abbreviations: IS, insulin sensitive patients; IR, insulin resistant patients; BMI,tioned.17 Insulin resistance was defined by the M-values
cutoff ,4.7.18,19 DNA samples were isolated from
200 mg of VAT. The anthropometric and clinical
characteristics of these subjects are shown in Table I.
DNA methylation and gene expression
analysis. Microarray-based DNA methylation analysis
was conducted with the Infinium Human Methylation
450 BeadChip (450K array; Illumina) following the Il-
lumina Infinium HD methylation protocol
(Supplementary Materials & methods). DNA quality
checks, bisulfite modification, hybridization, data
normalization, statistical filtering, and b value
calculations to assess the cytosine methylation states
were performed as described elsewhere.20,21
Pyrosequencing was used to assess selected markers
as aforementioned.22 Pyrosequencing reactions and
methylation quantification were performed in a
PyroMark Q96 ID System (Qiagen) using appropriate
reagents and protocols recommended by the manufac-
turer (details and primer sequences are available in the
Supplementary Methods). Gene expression was
assessed by real-time PCR using TaqMan technology
suitable for relative gene expression quantification in a
LightCycler 480 Real-Time PCR System (Rochesubjects from discovery and validation cohort
IR P-value
7
1/6
46.5 6 9.3 0.2
44.9 6 5.04 0.1
130.1 6 7.3 0.01
103.2 6 19.8 0.3
6.1 6 0.7 0.04
3.4 6 0.8 ,0.0001
194.7 6 45.6 0.7
123.5 6 36.4 0.8
43.8 6 9.7 0.03
136 (70–200) 0.2
0.73 (0.24–1.10) 0.3
11
1/10
48.8 6 6.8 0.4
45.3 6 6.6 0.9
124.4 6 10.3 0.4
95.2 6 7.2 0.8
5.73 6 0.31 0.3
2.51 6 1.2 ,0.0001
208.1 6 34.5 0.07
130.7 6 36.1 0.2
50.5 6 20.1 0.5
139 (117.7–159.5) 0.003
0.95 (0.65–1.38) 0.9
body mass index.
Translational Research
4 Crujeiras et al - 2016Diagnostics SL, Barcelona, Spain). The commercially
available and prevalidated TaqMan primer/probe sets
used were cyclophilin A (human peptidylprolyl isom-
erase A, 4333763, endogenous control) and zinc finger
protein 714 (ZNF714, Hs02743732_s1) from Life
Technologies S.A., Madrid, Spain. Fold changes rela-
tive to an endogenous control (PPIA) were determined
by calculating 22DCt.
Statistical analyses. Anthropometric and clinical
characteristics of individuals are expressed as
mean 6 standard deviation. Differences in these
data between IR and IS patients were tested by un-
paired Student t test. The methylation level of each
cytosine was expressed as a b value calculated as
the fluorescence intensity ratio of the methylated to
the unmethylated versions of the probes. The b values
ranged between 0 (unmethylated) and 1 (completely
methylated) according to a combination of the Cy3
and Cy5 fluorescence intensities. Color balance
adjustment and quantile normalization were per-
formed to normalize the samples between the 2 color
channels. b values with detection P-values .0.01
were considered to fall below the minimum intensity
and threshold, and these values were consequently
removed from further analysis. Approximately 96%
of the CpG islands were covered, along with regions
proximal to the CpG islands (‘‘CpG shores’’) and
the more distal CpG shelves. In addition, the probes
that were localized to the sex chromosomes and those
considered single nucleotide polymorphisms were
filtered out.
To identify consistent patterns of differentially meth-
ylated CpG sites (DMCpGs) between the IR and IS VAT
samples, nonparametric Wilcoxon rank-sum tests were
performed. P-values were adjusted for multiple compar-
isons using the false discovery rate procedure of Benja-
mini and Hochberg. In this analysis, a false discovery
rate below 5% (q value) was considered statistically sig-
nificant. However, given the sample size, we selected
the raw P-values of , 0.05 as a less stringent cutoff
for differential methylation than q values. In addition,
we applied a threshold for the significant sites based
on the mean differences between groups with a mini-
mum b value change of60.05. The P-values were rep-
resented in a Manhattan plot (2log10 of the P-value by
genomic location). Hierarchical cluster analysis of the
significant CpGs was performed using the heatmap
function. The overall distribution of significant CpG
sites compared with all analyzed sites on the Infinium
HumanMethylation 450 BeadChip was analyzed using
a chi-square test. All of the aforementioned statistical
analyses were performed using R software (version
3.2.0).To estimate the enrichment in biological processes, a
hypergeometric test was performed on the biological
processes defined by gene ontology (GO).23 This anal-
ysis detected the significant over-representation of GO
terms in one of the sets (ie, list of selected genes) with
respect to the other for the entire genome. GO terms
with an adjusted P-value of ,.05 were considered sig-
nificant.
Differences in DNA methylation levels detected by
pyrosequencing and expression of selected genes be-
tween groups were assessed by the nonparametric
Mann–Whitney U test using the SPSS version 17.0 soft-
ware (SPSS Inc, Chicago, Ill) for Windows XP (Micro-
soft, Redmond, Wash). P-values of # 0.05 were
considered statistically significant.RESULTS
Clinical characteristics of subjects with different degrees
of insulin sensitivity. Thirty-six morbid obese patients
were included in this study. The IS and IR individuals
were matched for age, gender, and body mass index in
both the discovery and the validation cohorts
(Table I). Statistically significant changes were
observed in parameters associated with insulin
resistance, such as waist circumference, HbA1c, and
lipid profile, in addition to differences in the M-clamp
value, as expected by design (Table I).
Differential DNA methylation in VAT from IR vs IS
patients. Direct comparison of the average of methyl-
ation levels of the 447,104 valid CpGs revealed rela-
tively similar global patterns between IR and IS
(Supplemental Fig S1A). The comparison of the DNA
methylation levels between IR and IS obese VATs
revealed 982 individual CpG sites that exhibit
differential DNA methylation $5% (P , .05) between
both groups (Supplemental Table S1). The change in
DNA methylation of individual CpG sites with a
significant difference between IR and IS (P , .05)
ranged from 20.38 to 0.77 (Supplemental Fig S1B),
and most of the differentially methylated CpG sites
(DMCpGs) presented absolute differences between
5% and 10%. No differences were observed in the
average DNA methylation levels of the 982 individual
DMCpG sites (Supplemental Fig S1C). A Manhattan
and a correlation plot between IR and IS patients are
shown in Supplemental Figures S1D and S1E,
respectively.
Genomic and chromosomal distribution of differentially
methylated CpG sites in IR VAT. The 982 identified CpG
sites were associated with 538 unique genes
(Supplemental Table S1). The majority were located
outside CpG-rich regions (CpG islands), mainly in the
open-sea region (Fig 1A). Moreover, the identified
Fig 1. Characterization of the CpG sites that exhibit differential DNAmethylation in insulin-resistant and insulin-
sensitive patients. (A) Genomic distribution of the differentially methylated CpG sites (DMCpGs) compared with
all the CpGs in the 450K array and in relation to their respective locations in the broader CpG context and (B) gene
region. CpG islands, areas of the genome with a high density of cytosine-phosphate-guanine (CpG) dinucleotides;
shores, areas of the genome up to 2 Kb from CpG islands; shelves, 2–4 Kb from CpG islands; open sea, .4 Kb
from CpG islands. (C) Supervised clustering of the CpGs that were found to be differentially methylated between
insulin-resistant and insulin-sensitive samples. *Denotes differences statistically significant (P , 0.05).
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between IR and IS were enriched within the intergenic
regions (Fig 1B). The CpG sites with decreased
methylation levels in IR with respect to IS VAT were
located in CpG islands and shores, whereas those with
increased methylation levels were located in the open-
sea region (Supplemental Fig S1F). The distribution
of gain and diminution of methylation in IR with
respect to that observed in IS samples was similar
regarding the respective location relative to genes
(Supplemental Fig S1G). With respect to the
chromosomic distribution of individual DMCpGs in
IR compared with IS, those DMCpGs with increased
methylation levels in IR were distributed in
chromosomes 1, 5, 6, 10, 11, and 13, whereas those
DMCpGs with decreased methylation levels in IR
were mainly found in chromosomes 12, 16, and 19(Supplemental Fig S1H). Importantly, the identified
CpG sites were able to perfectly differentiate the IR
and IS samples using a hierarchical cluster approach
(Fig 1C). Additional bioinformatics analysis of the
differently methylated regions yielded information
regarding the overlap of these regions with enhancers,
DNase hypersensitive, and open chromatin regions.
For that analysis, we exploited the state-of-the-art
Epic Illumina manifest, which provides information of
the chromosomal coordinates for this type of
important gene regulatory feature. This information
was determined by the ENCODE Consortium using
informatics and the original 450K consortia members.
This Epic updated manifest from Illumina contains
912 CpGs of the 980 DMCpGs in this study. Thus,
among the 912 CpGs, 257 CpGs were located in
enhancers, 541 were located in chromosomal
Translational Research
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were located in chromosomal coordinates of open
chromatin regions. Moreover, 247 CpGs of the 980
DMCpGs were located in promoters (Supplemental
Table S1).
Biological significance of the CpG sites and the
associated genes in IR. A GO analysis was performed
to test whether certain molecular functions or biological
processes were significantly associated with genes
showing a difference in DNA methylation status be-
tween IR and IS. Thus, among the significantly enriched
functional processes, the categories of cell adhesion,
signal transduction, and regulation of transcription ex-
hibited the largest number of genes (Fig 2A).
Relevantly, most of the genes differentially methylated
were significantly (P , .001) related and joined
with the insulin pathway (Fig 2B). Moreover, we
found 56 diabetes-associated genes according to the
Human Diabetes Proteome Project that were
represented by DMCpGs (Supplemental Table S2), 19
of which were located in promoter and island/shore
regions (Table II).
Regarding molecular functions or biological pro-
cesses, among the genes associated with cell adhesion,
CpG sites associated with COL9A1, COL11A2, and
CD44 exhibited higher methylation levels in IR than
in IS VAT, whereas CpG sites representing MUC4 and
ADAM2 showed lower levels in IR than in IS
(Fig 3A). Diminished methylation levels were also
observed in IR for genes involved in transcription func-
tion, such as PER3, GATA4, PRUMB, TXNIP1, and
ZNF714. Moreover HOXC4, TET1, FOXD2, and
NRBF2 exhibited increased methylation levels in IR
with respect to those in IS (Fig 3B). Including signal
transduction function, the methylation levels of
DMCpGs for TNFSF14 and ADCY9 were found to
have diminished in IR, whereas those coded by
IGF2R, CXCL12, CXCL13, FGF7, and FGF14 were
found to have increased in IR with respect to IS
(Fig 3C). In addition, although not statistically signifi-
cant in the GO analysis, genes with metabolic function
were identified by DMCpGs such as RAMP1, MUC4,
SULT1B1, HOX13, TBX5, FAMBA1, HADACM, and
SCG3 (Fig 3D).
A further analysis was performed by searching for
those 450k array probes located in island/shore pro-
moter regions with differences in absolute b values of
$ 0.10 and P-values of#0.01. Under these conditions,
11 CpG sites were detected. Among those, ZNF714was
selected because it was the gene with the largest methyl-
ation fold change and was represented by 5 consecutive
CpGs that were differentially methylated in the island/
shore promoter region (mean delta b 5 20.27;
P 5 .010).Methylation levels of ZNF714 in a validation cohort. We
used pyrosequencing to evaluate further DNA methyl-
ation levels for ZNF714. Thus, the differences in the
methylation levels of ZNF714 observed in the 450K
array (Fig 4A) were replicated by pyrosequencing in
the same cohort (Fig 4B). Importantly, the ZNF714
methylation pattern was further validated by
pyrosequencing in an independent cohort (validation
cohort, n 5 24; Table I; Fig 4C).
DNA methylation has previously been associated
with transcription repression.13 Accordingly, IR sam-
ples showed significantly (P 5 .04) higher expression
levels of the gene ZNF714 (0.0102 6 0.0025) than IS
(0.0052 6 0.0005), and this expression was associated
with the DNA methylation levels of ZNF714 (Fig 4D).
These results suggest that the epigenetic regulation of
this gene related to insulin sensitivity could have a rele-
vant biologic function.
DISCUSSION
In the current work, the genome-wide DNA methyl-
ation profile of VAT from morbidly obese patients
with insulin resistance was characterized, and potential
DNA methylation signatures of this metabolic disorder
were identified. This work demonstrates that VAT from
patients with disturbances in the insulin sensitivity pre-
sents a specific DNAmethylation pattern. DNAmethyl-
ation was altered in 982 CpG sites encoding 538 unique
genes with differences in beta values ranging from20.4
to 0.8. The identified genes were associated with func-
tions involved in cell adhesion, signal transduction,
and regulation of transcription. Relevantly, most of the
genes that were differentially methylated were joined
with the insulin pathway. In fact, 10% of the genes en-
coded by the DMCpGs in IR were identified as diabetes-
associated genes. Therefore, this study demonstrates
that the link between the dysfunction of VATand insulin
resistance may be epigenetically regulated, providing a
potential therapeutic target and biomarkers to coun-
teract this process.
In an obese state, adipose tissue becomes dysfunc-
tional. The tissue loses its capacity to store fatty acids
and presents altered adipokine production. This condi-
tion contributes to the etiology of obesity-related meta-
bolic complications such as insulin resistance.9 To date,
whether epigenetics play a role in adipose tissue
dysfunction has remained unknown.
The present study adds new and complementary in-
formation to previous studies in relation to T2D and
adiposity, supporting the potential role of epigenetics
in the development of insulin-sensitivity disturbances
in obesity. Previous studies have highlighted the impor-
tance of epigenetic regulation as a mechanism in the
pathogenesis of T2D.24 Detailed information
Fig 2. Biological implications of the differentially methylated CpG sites in insulin-resistant patients relative to
insulin-sensitive patients. (A) Summary of the gene ontology (GO) analysis of the biological process categories
for the differentially methylated genes represented by the DMCpG sites. (B) Gene-protein interaction network-
STRING analysis. Most of the genes regulated by methylation belong to a network significantly enriched in
insulin-related pathways (P, .001), according to STRING analysis. Red arrow shows insulin. (For interpretation
of the references to color in this figure legend, the reader is referred to the Web version of this article.)
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Table II. The differentially DNAmethylatedCpGs (DMCPGs) of diabetes-associated genes according to the HumanDiabetes Proteome Project (HDPP)
located in promoter and island and shore and sorted by chromosome
TargetID CHR Gene name CpG context Gene region
IS methylation
levels (mean)
IS methylation
levels (SD)
IR group
methylation
levels (mean)
IR group
methylation
levels (SD)
Differences
(IR-IS) P.value
cg22367705 1 SLC9A1 Island TSS200 0.04 0.01 0.10 0.13 0.07 0.005
cg11723801 1 NES Island 1stExon 0.10 0.03 0.15 0.04 0.05 0.030
cg08764927 1 PER3; PER3 Island 50UTR; 1stExon 0.64 0.04 0.58 0.05 20.06 0.048
cg00398048 4 AGA S_Shore TSS1500 0.31 0.07 0.23 0.05 20.08 0.030
cg07858113 6 IER3; FLOT1 Island 30UTR; TSS1500 0.23 0.07 0.15 0.03 20.08 0.048
cg00917413 7 CAV2; CAV2 N_Shore TSS1500; TSS1500 0.72 0.03 0.78 0.06 0.05 0.048
cg16490176 10 PLAU; C10orf55; PLAU Island TSS200; 30UTR; TSS200 0.30 0.02 0.25 0.03 20.05 0.010
cg16490176 10 PLAU; C10orf55; PLAU Island TSS200; 30UTR; TSS200 0.30 0.02 0.25 0.03 20.05 0.010
cg02114346 10 PAOX; PAOX; PAOX N_Shore TSS1500; TSS1500; TSS1500 0.61 0.03 0.55 0.03 20.06 0.010
cg08133496 11 EXT2; EXT2 N_Shore TSS200; TSS200 0.33 0.03 0.39 0.03 0.06 0.009
cg09558982 11 APOA1 S_Shore TSS200 0.35 0.07 0.45 0.09 0.11 0.048
cg17878506 13 TBC1D4 Island TSS1500 0.13 0.10 0.25 0.11 0.12 0.048
cg07470694 15 ATP10A S_Shore TSS1500 0.73 0.07 0.81 0.03 0.08 0.030
cg03077331 17 FN3K Island TSS1500 0.07 0.03 0.13 0.03 0.06 0.018
cg27457921 17 MAPT; MAPT; MAPT; MAPT;
MAPT; MAPT
S_Shore 50UTR; 50UTR; 50UTR;
50UTR; 50UTR; 50UTR
0.72 0.03 0.66 0.04 20.06 0.030
cg15104526 19 INSL3 Island TSS200 0.87 0.03 0.93 0.04 0.06 0.030
cg24292351 19 INSL3 Island TSS200 0.88 0.03 0.93 0.04 0.05 0.030
cg23484981 20 GNAS; GNAS; GNAS;
GNASAS
N_Shore TSS1500; TSS1500; 30UTR;
TSS1500
0.56 0.18 0.46 0.02 20.10 0.018
cg03529184 20 DEFB124; REM1 N_Shore TSS1500; TSS1500 0.52 0.05 0.59 0.03 0.07 0.030
Abbreviations: IS, insulin sensitive patients; IR, insulin resistant patients; SD, standard deviation.
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Fig 3. Genes with known functions that present differential DNA methylation in insulin-resistant and insulin-
sensitive patients. (A) Novel genes potentially involved in the onset of insulin resistance associated with
cell-adhesion function, (B) regulation of transcription function, (C) signal transduction function, and (D)
metabolic-related functions. DNA methylation values are expressed as b-values from the 450K array. *Denotes
differences statistically significant (P , 0.05).
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islets from T2D and nondiabetic patients has been pro-
vided.14,25 Genome-wide DNA methylation studies in
human skeletal muscle from individuals with or without
a family history of T2D have also indicated differential
methylation in genes involved in insulin signaling and
muscle function.26 Global methylation levels in subcu-
taneous adipose tissue are correlated with measures of
fat distribution and glucose homeostasis.15 Moreover,
differential methylation has previously been observed
in VAT of obese men discordant for metabolic syn-
drome.16 However, to the best of our knowledge, the
present study is the first to involve a DNA methylation
genome-wide analysis in VAT from morbidly obese pa-
tients in relation to insulin resistance by classifying pa-
tients according to the gold-standard technique for
evaluating insulin sensitivity.
The IR-related DMCpGs were distributed mainly in
the intergenic and open-sea regions, in agreement with
what has been previously reported in white adipose tis-
sue27,28 and in isolated fat cells in relation to adiposity29
and T2D26 and metabolic syndrome.16 The mean
magnitude of the absolute differences in beta valueswas small, in line with that observed in previous studies
of adipose tissue.16,29-31 Although previous studies have
reported global hypomethylation associated with
T2D,24 in the present study no differences were
observed in the global methylation levels between IR
and IS morbidly obese patients. However, the differen-
tial methylation analysis between IR and IS patients re-
vealed genes involved in pathways associated with the
function of adipose tissue, such as cell adhesion, signal
transduction, and regulation of transcription. Rele-
vantly, in agreement with the role of VAT in insulin
resistance and future T2D onset, a significant number
of genes mapped by the DMCpGs between IR and IS
were associated with the insulin pathway and belong
to the list of genes related to T2D.
Regarding the mechanism involved in the obesity-
related dysregulation of adipose tissue, several lines of
evidence suggest that the remodeling of the extracellular
matrix, particularly collagens, is essential for adipocyte
and adipose tissue expansion, which is dysregulated in
an obese state.32 In agreement with the epigenetic point
of view of this proposal, because novel IR-related genes
are epigenetically regulated in VAT, the current work
Fig 4. DNA methylation of ZNF714 is associated with a decrease in
gene expression. (A) DNA methylation differences between IS and
IR VAT samples from the discovery cohort measured by the 450K
array. (B) DNA methylation differences between IS and IRVAT sam-
ples measured by pyrosequencing from the discovery and (C) valida-
tion cohort. (D) Differential gene expression of ZNF714 between IS
and IR VAT samples. IS, insulin sensitivity; IR, insulin resistance;
VAT, visceral adipose tissue. *Denotes differences statistically signif-
icant (P , 0.05).
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related genes such as COL9A1 and COL11A2 together
with other genes included in the cell-adhesion category
of functional processes, such as CD44, MUC4, and
ADAM2. In addition, the analysis identified relevant
genes mapped by more than 2 CpG sites that could
play a crucial role in the development of IR induced by
dysfunctional VAT, such as GATA4, TET1, ZNF714,
ADCY9, TBX5, and HDACM. Among these, the tran-
scription factor GATA4 has been studied in the cardiac
system to promote hypertrophy and mediate the leptin-
induced vascular,33 suggesting a putative role of this
gene in hypertension associated with obesity. Moreover,
it was discovered that the loss of intestinal GATA4 pre-
vents diet-induced obesity, promotes insulin sensitivity,34
and protects against diet-induced hepatic steatosis34 in
mice. TET1 is a demethylase that was shown to regulate
epigenetically insulin-like growth factor 2 mRNA bind-
ing protein 1.35 TBX5 is a developmental gene that pre-
sented 4 DMCpGs. The gene was identified as a
regulator of preadipocyte proliferation and adipogenic
differentiation in abdominal adipose tissue under epige-
netic control.36 The zinc finger protein 714 (ZNF714) ex-
hibited the highest DNA methylation difference and was
mapped by 5 DMCpGs located in island/shore and pro-
moter regions. The gene was found to present lower
methylation levels in IR than in IS patients in association
with increased transcription levels. Even though the func-
tional association with the development of IR or T2D re-
mains to be elucidated, future exploration of the role of
this gene could reveal a novel mechanism involved in
the development of IR and T2D in line with other zinc
finger proteins, which are associated with adipogene-
sis,37,38 T2D, or insulin resistance.39,40
The strength of this study is that it was performed in
a homogeneous population classified according to in-
sulin sensitivity measured by the gold-standard tech-
nique for detecting dysregulation in insulin action.
The relatively small sample size is a limitation of
this study. Obtaining visceral adipose tissue from a
homogeneous population of subjects in whom insulin
action is measured using a euglycemic clamp remains
a challenge. However, the statistical significance
observed when using small populations typically in-
dicates that there is a real difference between experi-
mental groups. We decided to use P-values for
differential methylation without correction for multi-
ple testing because of the relatively small sample size.
Therefore, the results should be interpreted
cautiously. However, subsequent analyses were per-
formed with highly stringent filters to gain consistent
results, which were further validated in an indepen-
dent cohort. Although the magnitude of the DNA
SUPPLEMENTARY DATA
Supplementary data related to this article can be
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considered small, these differences may have been
observed because of the use of complex tissue instead
of a single cell but also because the intergroup patho-
physiological differences were within a narrow range
of insulin action.
In conclusion, the present study demonstrates the ex-
istence of a specific methylome map associated with in-
sulin resistance in VAT. This IR-related methylome
exhibits a potential epigenetic regulation involved in
the dysregulation of VAT that could predispose to insu-
lin resistance and future T2D onset in morbidly obese
patients. To the best of our knowledge, this study is
the first to investigate the global methylome of VATob-
tained from patients in the clinical setting of morbid
obesity with and without insulin resistance. Further
research based on the results obtained from this study
will open new avenues for studying the role of VAT in
driving insulin resistance and future T2D by identifying
potential epigenetic biomarkers and novel therapeutic
targets in the prevention and treatment of these meta-
bolic disturbances.
ACKNOWLEDGMENTS
Conflicts of Interest: All authors have read the jour-
nal’s policy on disclosure of potential conflicts of inter-
est and have none to declare.
The authors thank Maria Amil and Maribel Rendo
from Instituto de Investigacion Sanitaria de Santiago
de Compostels (CHUS-IDIS), Spain, and Diana Garcıa
and Carles Arribas from the Bellvitge Biomedical
Research Institute (IDIBELL), Spain, for their technical
support, as well as the Fatbank from the CIBER Fisiopa-
tologia de la Obesidad y Nutricion (CIBERobn), Spain.
This work was supported by grants from the Fondo de
Investigacion Sanitaria (FIS 2011/00214 and PI14/
01012), and CIBER Fisiopatologia de la Obesidad y Nu-
tricion (CIBERobn; CB06/003), Instituto de SaludCarlos
III (ISCIII)-FEDER, Spanish Ministry of Health, Spain;
the European Research Council (ERC) grant EPINORC
(268626) and the Health and Science Departments of
the Catalan Government (Generalitat de Catalunya),
Spain. A.B. Crujeiras was funded by the ISCIII through
a ‘‘Sara Borrell’’ research contract (C09/00365) and the
Health Department of the Xunta the Galicia, Spain.
A. Diaz-Lagares. was funded by the ISCIII through a
‘‘Rıo Hortega’’ research contract (CM14/00067). J. San-
doval is a ‘‘Miguel Servet’’ (MS13/00055) researcher. M.
Esteller. is an ICREA Research Professor.
A.B. Crujeiras and A. Diaz-Lagares designed the ex-
periments, analyzed the data, and wrote the manuscript.
J. M. Moreno-Navarrete, J. Sandoval, D. Hervas, and
A. Gomez analyzed the data. W. Ricart, F. F. Casanueva,
and M. Esteller contributed to discussions and reviewedthe manuscript. J. M. Fernandez-Real designed the ex-
periments, contributed to discussions, and reviewed the
manuscript. A.B. Crujeiras and J. M. Fernandez-Real
are the guarantors of this work and, as such, had full ac-
cess to all the data in the study and take responsibility for
the integrity of the data and the accuracy of the data anal-
ysis. All authors have reviewed and approved the article
and have read the journal’s authorship agreement.REFERENCES
1. Calori G, Lattuada G, Piemonti L, et al. Prevalence, metabolic
features, and prognosis of metabolically healthy obese Italian in-
dividuals: the Cremona Study. Diabetes Care 2011;34:210–5.
2. Qiao Q, Gao W, Zhang L, Nyamdorj R, Tuomilehto J. Metabolic
syndrome and cardiovascular disease. Ann Clin Biochem 2007;
44:232–63.
3. Reaven GM. Insulin resistance: the link between obesity and car-
diovascular disease. Endocrinol Metab Clin North Am 2008;37:
581–601, vii–viii.
4. Arcidiacono B, Iiritano S, Nocera A, et al. Insulin resistance and
cancer risk: an overview of the pathogenetic mechanisms. Exp
Diabetes Res 2012;2012:789174.
5. Goodpaster BH, Thaete FL, Simoneau JA, Kelley DE. Subcutane-
ous abdominal fat and thigh muscle composition predict insulin
sensitivity independently of visceral fat. Diabetes 1997;46:
1579–85.
6. Kelley DE, Thaete FL, Troost F, Huwe T, Goodpaster BH. Subdi-
visions of subcutaneous abdominal adipose tissue and insulin
resistance. Am J Physiol Endocrinol Metab 2000;278:E941–8.
7. Bonora E, Del Prato S, Bonadonna RC, et al. Total body fat con-
tent and fat topography are associated differently with in vivo
glucose metabolism in nonobese and obese nondiabetic women.
Diabetes 1992;41:1151–9.
8. ZhangM,Hu T, Zhang S, Zhou L. Associations of different adipose
tissue depots with insulin resistance: a systematic review and meta-
analysis of observational studies. Sci Rep 2015;5:18495.
9. Lee MJ, Wu Y, Fried SK. Adipose tissue heterogeneity: implica-
tion of depot differences in adipose tissue for obesity complica-
tions. Mol Aspects Med 2013;34:1–11.
10. Elder SJ, Lichtenstein AH, Pittas AG, et al. Genetic and environ-
mental influences on factors associated with cardiovascular dis-
ease and the metabolic syndrome. J Lipid Res 2009;50:1917–26.
11. Hamilton JP. Epigenetics: principles and practice. Dig Dis 2011;
29:130–5.
12. Portela A, Esteller M. Epigenetic modifications and human dis-
ease. Nat Biotechnol 2010;28:1057–68.
13. Crujeiras AB, Dıaz-Lagares A. DNA methylation in obesity and
associated diseases. In: Garcia-Gimenez J, ed. Epigenetic bio-
markers and diagnostics. Valencia: Elsevier, 2016:313–29.
14. Dayeh T, Volkov P, Salo S, et al. Genome-wide DNA methylation
analysis of human pancreatic islets from type 2 diabetic and non-
diabetic donors identifies candidate genes that influence insulin
secretion. PLoS Genet 2014;10:e1004160.
15. Keller M, Kralisch S, Rohde K, et al. Global DNA methylation
levels in human adipose tissue are related to fat distribution and
glucose homeostasis. Diabetologia 2014;57:2374–83.
Translational Research
12 Crujeiras et al - 201616. Guenard F, Tchernof A, Deshaies Y, et al. Differential methylation
in visceral adipose tissue of obese men discordant for metabolic
disturbances. Physiol Genomics 2014;46:216–22.
17. Jove M, Moreno-Navarrete JM, Pamplona R, Ricart W, Portero-
Otin M, Fernandez-Real JM. Human omental and subcutaneous
adipose tissue exhibit specific lipidomic signatures. Faseb J
2014;28:1071–81.
18. Bergman RN, Finegood DT, AderM. Assessment of insulin sensi-
tivity in vivo. Endocr Rev 1985;6:45–86.
19. Tam CS, Xie W, Johnson WD, Cefalu WT, Redman LM,
Ravussin E. Defining insulin resistance from hyperinsulinemic-
euglycemic clamps. Diabetes Care 2012;35:1605–10.
20. Sandoval J, Heyn H, Moran S, et al. Validation of a DNA methyl-
ation microarray for 450,000 CpG sites in the human genome.
Epigenetics 2011;6:692–702.
21. Heyn H, Carmona FJ, Gomez A, et al. DNAmethylation profiling
in breast cancer discordant identical twins identifies DOK7 as
novel epigenetic biomarker. Carcinogenesis 2012;34:102–8.
22. Heyn H, Li N, Ferreira HJ, et al. Distinct DNA methylomes of
newborns and centenarians. Proc Natl Acad Sci U S A 2012;
109:10522–7.
23. Falcon S, Gentleman R. Using GOstats to test gene lists for GO
term association. Bioinformatics 2007;23:257–8.
24. Ronn T, Ling C. DNAmethylation as a diagnostic and therapeutic
target in the battle against type 2 diabetes. Epigenomics 2015;7:
451–60.
25. VolkmarM, Dedeurwaerder S, CunhaDA, et al. DNAmethylation
profiling identifies epigenetic dysregulation in pancreatic islets
from type 2 diabetic patients. Embo J 2012;31:1405–26.
26. Nitert MD, Dayeh T, Volkov P, et al. Impact of an exercise inter-
vention on DNA methylation in skeletal muscle from first-degree
relatives of patients with type 2 diabetes. Diabetes 2012;61:
3322–32.
27. Nilsson E, Jansson PA, Perfilyev A, et al. Altered DNA methyl-
ation and differential expression of genes influencing metabolism
and inflammation in adipose tissue from subjects with type 2 dia-
betes. Diabetes 2014;63:2962–76.
28. Ronn T, Volkov P, Davegardh C, et al. A six months exercise inter-
vention influences the genome-wide DNA methylation pattern in
human adipose tissue. PLoS Genet 2013;9:e1003572.29. Arner P, Sinha I, Thorell A, Ryden M, Dahlman-Wright K,
Dahlman I. The epigenetic signature of subcutaneous fat cells is
linked to altered expression of genes implicated in lipid meta-
bolism in obese women. Clin Epigenetics 2015;7:93.
30. Benton MC, Johnstone A, Eccles D, et al. An analysis of DNA
methylation in human adipose tissue reveals differential modifica-
tion of obesity genes before and after gastric bypass and weight
loss. Genome Biol 2015;16:8.
31. Dahlman I, Sinha I, Gao H, et al. The fat cell epigenetic signature
in post-obese women is characterized by global hypomethylation
and differential DNA methylation of adipogenesis genes. Int J
Obes (Lond) 2015;39:910–9.
32. Denis GV, Obin MS. ‘Metabolically healthy obesity’: origins and
implications. Mol Aspects Med 2013;34:59–70.
33. Ghantous CM, Kobeissy FH, Soudani N, et al. Mechanical
stretch-induced vascular hypertrophy occurs through modulation
of leptin synthesis-mediated ROS formation and GATA-4 nuclear
translocation. Front Pharmacol 2015;6:240.
34. Patankar JV, Obrowsky S, Doddapattar P, et al. Intestinal GATA4
deficiency protects from diet-induced hepatic steatosis. J Hepatol
2012;57:1061–8.
35. Mahaira LG, Katsara O, Pappou E, et al. IGF2BP1 expression in
humanmesenchymal stem cells significantly affects their prolifer-
ation and is under the epigenetic control of TET1/2 demethylases.
Stem Cells Dev 2014;23:2501–12.
36. Pinnick KE, Nicholson G, Manolopoulos KN, et al. Distinct
developmental profile of lower-body adipose tissue defines resis-
tance against obesity-associated metabolic complications. Dia-
betes 2014;63:3785–97.
37. Kang S, Akerblad P, Kiviranta R, et al. Regulation of early adipose
commitment by Zfp521. PLoS Biol 2012;10:e1001433.
38. Gupta RK, Arany Z, Seale P, et al. Transcriptional control of pre-
adipocyte determination by Zfp423. Nature 2010;464:619–23.
39. Jia Y, Yuan L, Hu W, et al. Zinc-finger BED domain-containing 3
(Zbed3) is a novel secreted protein associated with insulin resis-
tance in humans. J Intern Med 2014;275:522–33.
40. Scherneck S, Vogel H, Nestler M, Kluge R, Schurmann A,
Joost HG. Role of zinc finger transcription factor zfp69 in body
fat storage and diabetes susceptibility of mice. Results Probl
Cell Differ 2010;52:57–68.
Translational Research
Volume-, Number- Crujeiras et al 12.e1APPENDIX
SUPPLEMENTARY METHODS
DNA preparation and bisulfite conversion. DNA from
fresh-frozen (FF) tissue samples was isolated using a
standard phenol-chloroform/proteinase-k protocol. After
proteinase-K incubation, adipose tissue homogenates
were centrifuged (13000 g, 2C, 30 min) to avoid lipid
interference in the DNA purification process. The
obtained DNA was treated with RNase A for 1 hour at
45C. All DNA samples were quantified using the
fluorometric method (Quan-iT PicoGreen DsDNA
Assay, Life Technologies) and were assessed for purity
using a NanoDrop (Thermo Scientific) with 260/280 and
260/230 ratio measurements. The integrity of the FF
DNA was verified by electrophoresis in 1.3% agarose
gel. FF DNA (600 ng) was processed using the EZ-96
DNA Methylation kit (Zymo Research Corp.) following
the manufacturer’s recommendations for Infinium assays.
DNA methylation analysis.
Infinium Human Methylation 450 BeadChip array. Mi-
croarray–based DNA methylation analysis was con-
ducted with the Infinium Human Methylation 450
BeadChip (450K array). DNA quality checks, bisulfite
modification, hybridization, data normalization, statisti-
cal filtering, and b value calculations were performed as
described elsewhere.20 High-quality DNA samples ob-
tained from subcutaneous adipose tissue and leukocytes
were selected for bisulfite conversion (Zymo Research;
EZ-96 DNA Methylation Kit) and hybridization to the
Infinium Human Methylation 450 BeadChips (Illu-
mina) following the Illumina Infinium HD methylation
protocol. The DNA concentration of the quality-control
sample standards was measured using the PicoGreen
method (Invitrogen) coupled with assessments of
DNA purity based on the A260/A280 ratio (ranging be-
tween 1.75 and 1.95) and the A260/A230 ratio (ranging
between 2.00 and 2.20). Analysis with 1% agarose gel
electrophoresis allowed for the exclusion of samples
with possible DNA fragmentation or RNA contamina-
tion. The Infinium Human Methylation 450 BeadChip
provides coverage of .450,000 CpG sites targeting
nearly all of the RefSeq genes (.99%).20 The chips
were designed to cover the coding and noncoding genes
without bias against those lacking CpG islands. The
design further aimed to cover not only promoter regula-
tory regions but also CpGs across gene regions to
include the 50-untranslated regions, the first exons, the
gene bodies, and the 30-untranslated regions.
In total, 600 ng from the high-quality DNA samples
was bisulfite converted. Whole-genome amplificationand hybridization were then performed on the BeadChip
and followed by single-base extension and analysis on a
HiScan SQ module (Illumina) to assess the cytosine
methylation states. The annotation of the CpG islands
(CGI) involved the following categorization1: shore,
for each of the 2-Kb sequences flanking a CGI2; shelf,
for each of the 2-kb sequences next to a shore; and3
open sea, for DNA not included in any of the previous
sequences or in CGIs.21 The transcription start site
200 and the transcription start site 1500 indicate the re-
gions either 200 or 1500 bp from the transcription start
site, respectively.
Pyrosequencing analysis. Pyrosequencing was used to
assess selected markers as previously described.22 The
primer sequences used in this analysiswere designed using
Qiagen’s PyroMark Assay Design 2.0 software to hybrid-
ize to CpG-free sites to ensure methylation-independent
amplification. Briefly, polymerase chain reaction (PCR)
was performed using standard conditionswith biotinylated
primers, and the PyroMark Vacuum Prep Tool (Biotage,
Uppsala, Sweden) was used to prepare single-stranded
PCR products according to the manufacturer’s instruc-
tions. Pyrosequencing reactions and methylation quantifi-
cation were performed in a PyroMarkQ96 System version
2.0.6 (Qiagen), using appropriate reagents and recommen-
ded protocols. The primer sequences used were (all given
50 . 03): ZNF714 prePCR fwd: [Btn]GGAAGTTTA-
GAAATGGTGAGAGT, ZNF714 pre-PCR reverse:
CCCCTAAAACCCTCCAATAATC, ZNF714 seq:
AATCCCTACACAATCC.
Gene expression analyses. Briefly, RNA purification
was performed using the RNeasy Lipid Tissue Mini Kit
(Qiagen, Izasa SA, Barcelona, Spain), and the integrity
was verified using an Agilent Bioanalyzer (Agilent Tech-
nologies, Palo Alto, Calif). Gene expression was assessed
by real-time PCR using TaqMan technology suitable for
relative genetic-expression quantification in a
LightCycler 480 Real-Time PCR System (Roche
Diagnostics SL, Barcelona, Spain). The RT-PCR
reaction was performed in a final volume of 12 ml. The
cycle program consisted of an initial denaturing of
10 minutes at 95C and then 40 cycles of 15 seconds
denaturizing phase at 95C and a 1 minute annealing
and extension phase at 60C. A threshold cycle (Ct
value) was obtained for each amplification curve, and a
DCt value was first calculated by subtracting the Ct
value for human peptidylprolyl isomerase A (cyclophilin
A; PPIA) RNA from the Ct value for each sample. Fold
changes relative to the endogenous control were then
determined by calculating 22DCt; therefore, gene-
expression results are expressed as the expression ratio
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manufacturers’ guidelines. The commercially available
and prevalidated TaqMan primer/probe sets used were asSupplementary Fig 1. (A) Differences in the global average
the insulin-resistant (IR) and insulin-sensitivity (IS) samples.
among the differentially methylated CpG sites. (C) Global d
tially methylated CpGs identified by the 450K array analys
values of association. The y axis shows the 2log10(p) value
chromosomal position. The horizontal discontinuous line rep
entially methylated CpG sites. (E). Correlation of the methy
and IS. (F–H). Genomic distributions of the differentially m
an increase with those that exhibited a decrease in methylatio
CpG context, the gene region, and chromosome distributionfollows: PPIA (4333763, endogenous control) and zinc
finger protein 714 (ZNF714, Hs02743732_s1; Life
Technologies S.A., Madrid, Spain).methylation levels of the overall valid CpGs between
(B) Range of differences between IR and IS samples
ifferences in the methylation levels of the differen-
is. (D) Manhattan plot showing epigenome-wide P-
s of 447,104 valid CpGs, and the x axis shows their
resents the threshold of P, .05 for selecting differ-
lation levels between a representative sample of IR
ethylated CpG sites comparing those that exhibited
n levels and their respective locations in the broader
, respectively.
Supplementary Table II. Differentially DNA methylated CpGS (DMCPGs) of diabetes-associated genes according to the Human Diabetes Proteome
Project (HDPP)
TargetID CHR Gene name CpG context Gene region
IS
methylation
levels
(mean)
IS
methylation
levels (SD)
IR group
methylation
levels
(mean)
IR group
methylation
levels (SD)
Differences
(IR-IS)
P.
value
cg08764927 1 PER3; PER3 Island 50UTR; 1stExon 0.64 0.04 0.58 0.05 20.06 0.048
cg13457410 1 PIK3CD 50UTR 0.13 0.04 0.22 0.06 0.09 0.018
cg22367705 1 SLC9A1 Island TSS200 0.04 0.01 0.10 0.13 0.07 0.005
cg19693031 1 TXNIP 30UTR 0.51 0.04 0.44 0.05 20.06 0.048
cg11723801 1 NES Island 1stExon 0.10 0.03 0.15 0.04 0.05 0.030
cg09470983 3 TFRC; TFRC N_Shelf 50UTR; 50UTR 0.74 0.06 0.67 0.03 20.07 0.018
cg00398048 4 AGA S_Shore TSS1500 0.31 0.07 0.23 0.05 20.08 0.030
cg23210478 5 EBF1 Body 0.41 0.06 0.50 0.04 0.08 0.030
cg10784548 5 NSD1; NSD1 Body; body 0.53 0.05 0.46 0.07 20.07 0.048
cg05554718 6 HIST1H1D TSS1500 0.73 0.02 0.56 0.26 20.17 0.030
cg17977304 6 MOG; MOG; MOG; MOG;
MOG; MOG; MOG; MOG;
MOG; MOG; MOG
TSS1500; TSS1500;
TSS1500; TSS1500;
TSS1500; TSS1500;
TSS1500; TSS1500;
TSS1500; TSS1500;
TSS1500
0.30 0.03 0.37 0.06 0.06 0.048
cg07858113 6 IER3; FLOT1 Island 30UTR; TSS1500 0.23 0.07 0.15 0.03 20.08 0.048
cg20549346 6 C6orf10 Body 0.32 0.35 0.74 0.03 0.42 0.003
cg08265274 6 HLA-DRB5 S_Shore Body 0.40 0.11 0.23 0.12 20.17 0.030
cg07984380 6 HLA-DRB1 Body 0.03 0.00 0.26 0.20 0.24 0.030
cg13910785 6 HLA-DRB1 N_Shelf Body 0.01 0.02 0.23 0.33 0.22 0.034
cg19575208 6 HLA-DRB1 Island Body 0.46 0.10 0.30 0.11 20.16 0.018
cg08845336 6 HLA-DRB1 Island Body 0.47 0.15 0.30 0.11 20.17 0.030
cg08231637 6 HLA-DRB1 Body 0.03 0.06 0.48 0.30 0.45 0.039
cg10385522 6 HLA-DRB1 TSS1500 0.00 0.00 0.55 0.45 0.55 0.012
cg14799809 6 HLA-DQA1 Body 0.39 0.46 0.82 0.22 0.42 0.048
cg03638120 6 HLA-DQB2 Island Body 0.36 0.04 0.41 0.04 0.05 0.030
cg18599231 6 HLA-DOB TSS1500 0.54 0.01 0.47 0.04 20.06 0.003
cg08327277 6 TAP2; TAP2 30UTR; body 0.79 0.03 0.73 0.04 20.05 0.018
cg25283336 6 HLA-DPA1 30UTR 0.92 0.01 0.83 0.10 20.09 0.010
cg13726184 6 IGF2R S_Shelf Body 0.59 0.05 0.65 0.03 0.06 0.010
cg23347850 7 ICA1; ICA1; ICA1 50UTR; 50UTR; 50UTR 0.51 0.04 0.57 0.04 0.06 0.048
cg00917413 7 CAV2; CAV2 N_Shore TSS1500; TSS1500 0.72 0.03 0.78 0.06 0.05 0.048
cg07571734 7 PRKAG2; PRKAG2 N_Shore Body; body 0.23 0.02 0.17 0.04 20.06 0.010
cg02860921 7 PTPRN2; PTPRN2; PTPRN2 S_Shelf Body; body; body 0.69 0.01 0.75 0.03 0.06 0.005
cg11468861 7 PTPRN2; PTPRN2; PTPRN2 Body; body; body 0.44 0.04 0.51 0.06 0.06 0.048
cg15727524 7 PTPRN2; PTPRN2; PTPRN2 Body; body; body 0.27 0.02 0.32 0.03 0.05 0.018
cg15807855 7 PTPRN2; PTPRN2; PTPRN2 Body; body; body 0.50 0.02 0.55 0.03 0.06 0.003
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Supplementary Table II. (Continued )
TargetID CHR Gene name CpG context Gene region
IS
methylation
levels
(mean)
IS
methylation
levels (SD)
IR group
methylation
levels
(mean)
IR group
methylation
levels (SD)
Differences
(IR-IS)
P.
value
cg11062158 7 PTPRN2; PTPRN2; PTPRN2 N_Shore Body; body; body 0.98 0.01 0.92 0.04 20.06 0.010
cg06152586 7 PTPRN2; PTPRN2; PTPRN2 Island Body; body; body 0.82 0.07 0.69 0.09 20.14 0.048
cg00369194 7 PTPRN2; PTPRN2; PTPRN2 N_Shore Body; body; body 0.71 0.05 0.61 0.06 20.09 0.018
cg09409457 7 PTPRN2; PTPRN2; PTPRN2 N_Shelf Body; body; body 0.71 0.05 0.77 0.04 0.06 0.030
cg23602909 7 PTPRN2; PTPRN2; PTPRN2 N_Shore Body; body; body 0.71 0.03 0.77 0.05 0.06 0.048
cg08955548 7 PTPRN2; PTPRN2; PTPRN2 N_Shore Body; body; body 0.65 0.05 0.77 0.09 0.11 0.048
cg27194152 7 PTPRN2; PTPRN2; PTPRN2 S_Shore Body; body; body 0.91 0.02 0.86 0.04 20.05 0.048
cg20528787 7 PTPRN2; PTPRN2; PTPRN2 Body; body; body 0.49 0.08 0.39 0.07 20.10 0.030
cg02770061 7 PTPRN2; PTPRN2; PTPRN2 Body; body; body 0.81 0.06 0.73 0.05 20.07 0.018
cg12834378 7 PTPRN2; PTPRN2; PTPRN2 Body; body; body 0.76 0.05 0.67 0.03 20.09 0.010
cg10993470 8 RP1 Island Body 0.90 0.05 0.96 0.02 0.06 0.048
cg24222992 10 CAMK1D; CAMK1D Body; body 0.78 0.03 0.83 0.03 0.05 0.018
cg02928885 10 GAD2; GAD2 Body; body 0.53 0.04 0.59 0.03 0.07 0.005
cg10031769 10 CREM; CREM; CREM;
CREM; CREM; CREM;
CREM; CREM; CREM;
CREM; CREM; CREM;
CREM; CREM;
CREM; CREM;
CREM; CREM;
CREM; CREM
Body; body; body;
body; TSS200;
50UTR;
TSS200; TSS1500;
body; TSS1500;
TSS1500;
TSS1500; 50UTR;
body; body;
TSS1500;
TSS200; body; body;
TSS200
0.75 0.02 0.69 0.05 20.06 0.048
cg07001963 10 CXCL12; CXCL12; CXCL12 N_Shore Body; body; body 0.22 0.04 0.27 0.05 0.05 0.048
cg16490176 10 PLAU; C10orf55; PLAU Island TSS200; 30UTR;
TSS200
0.30 0.02 0.25 0.03 20.05 0.010
cg16490176 10 PLAU; C10orf55; PLAU Island TSS200; 30UTR;
TSS200
0.30 0.02 0.25 0.03 20.05 0.010
cg08604416 10 SORBS1; SORBS1 50UTR; 50UTR 0.62 0.03 0.68 0.03 0.06 0.018
cg03440556 10 SCD S_Shore Body 0.32 0.04 0.40 0.06 0.08 0.030
cg16106427 10 STK32C S_Shelf Body 0.88 0.02 0.82 0.04 20.05 0.030
cg02114346 10 PAOX; PAOX; PAOX N_Shore TSS1500; TSS1500;
TSS1500
0.61 0.03 0.55 0.03 20.06 0.010
cg14593191 11 CD44; CD44; CD44;
CD44; CD44
Body; body; body;
body; body
0.37 0.02 0.44 0.02 0.06 0.003
cg08133496 11 EXT2; EXT2 N_Shore TSS200; TSS200 0.33 0.03 0.39 0.03 0.06 0.009
cg04827223 11 ARAP1 N_Shore Body 0.80 0.03 0.75 0.03 20.06 0.010
cg09558982 11 APOA1 S_Shore TSS200 0.35 0.07 0.45 0.09 0.11 0.048
cg12823408 11 ARHGEF12 30UTR 0.74 0.18 0.84 0.02 0.10 0.048
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cg15381313 12 NR1H4 TSS200 0.49 0.05 0.56 0.04 0.07 0.018
cg18874332 12 NR1H4 TSS200 0.22 0.04 0.28 0.05 0.06 0.030
cg03771004 12 NR1H4; NR1H4 50UTR; 1stExon 0.64 0.03 0.70 0.03 0.06 0.010
cg07472750 13 HMGB1 50UTR 0.00 0.01 0.06 0.04 0.05 0.033
cg17878506 13 TBC1D4 Island TSS1500 0.13 0.10 0.25 0.11 0.12 0.048
cg16421871 13 MCF2L; MCF2L N_Shore Body; body 0.34 0.06 0.25 0.05 20.08 0.048
cg05008070 14 DACT1; DACT1 S_Shore Body; body 0.54 0.06 0.61 0.04 0.06 0.048
cg07470694 15 ATP10A S_Shore TSS1500 0.73 0.07 0.81 0.03 0.08 0.030
cg01512138 16 CLEC16A Body 0.56 0.04 0.61 0.04 0.05 0.048
cg27457921 17 MAPT; MAPT; MAPT;
MAPT; MAPT; MAPT
S_Shore 50UTR; 50UTR; 50UTR;
50UTR; 50UTR; 50UTR
0.72 0.03 0.66 0.04 20.06 0.030
cg03077331 17 FN3K Island TSS1500 0.07 0.03 0.13 0.03 0.06 0.018
cg26446133 18 CNDP2; CNDP2; CNDP2 S_Shelf 50UTR; 1stExon; 50UTR 0.68 0.07 0.40 0.26 20.28 0.048
cg21586152 19 ELANE N_Shore Body 0.61 0.04 0.54 0.05 20.07 0.048
cg15104526 19 INSL3 Island TSS200 0.87 0.03 0.93 0.04 0.06 0.030
cg24292351 19 INSL3 Island TSS200 0.88 0.03 0.93 0.04 0.05 0.030
cg14061069 19 DMPK; DMPK;
DMPK; DMPK
Island Body; body; body; body 0.40 0.04 0.32 0.06 20.07 0.030
cg03529184 20 DEFB124; REM1 N_Shore TSS1500; TSS1500 0.52 0.05 0.59 0.03 0.07 0.030
cg23303369 20 MMP9 Island Body 0.33 0.05 0.39 0.03 0.06 0.048
cg23484981 20 GNAS; GNAS;
GNAS; GNASAS
N_Shore TSS1500; TSS1500;
30UTR; TSS1500
0.56 0.18 0.46 0.02 20.10 0.018
cg17505852 22 NF2; NF2; NF2; NF2; NF2;
NF2; NF2; NF2; NF2
S_Shelf Body; body; body;
body; body;
body; body;
Body; body
0.57 0.05 0.63 0.02 0.06 0.030
Abbreviations: IS, insulin sensitive patients; IR, insulin resistant patients; SD, standard deviation.
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